Emergence of ST131 carrying carbapenemase genes, European Union/European Economic Area, August 2012 to May 2024. [1]
Peer reviewed scientific article
Engels
SCIENSANO
Auteurs
Anke Kohlenberg [3]; Olov Svartström [4]; Petra Apfalter [5]; Rainer Hartl [6]; Bogaerts, Pierre [7]; Huang, Te-Din [8]; Katerina Chudejova [9]; Lucia Malisova [10]; Jessica Eisfeld [11]; Mirco Sandfort [12]; Anette M Hammerum [13]; Louise Roer [14]; Kati Räisänen [15]; Laurent Dortet [16]; Rémy A Bonnin [17]; Tóth, Ákos [18]; Kinga Tóth [19]; Christina Clarke [20]; Martin Cormican [21]; Algirdas Griskevicius [22]; Kirstin Khonyongwa [23]; Marie Meo [24]; Niedre-Otomere, Baiba [25]; Reinis Vangravs [26]; Antoni Pa Hendrickx [27]; Daan W Notermans [28]; Samuelsen, Ørjan [29]; Manuela Caniça [30]; Vera Manageiro [31]; Vilhelm Müller [32]; Barbro Mäkitalo [33]; Urška Kramar [34]; Mateja Pirs [35]; Daniel Palm [36]; Dominique L Monnet [37]; Erik Alm [38]; Marius Linkevicius [39]Trefwoorden
Article written during project(s) :
Samenvatting:
Analysis of 594 isolates of sequence type (ST)131 and its single locus variants carrying carbapenemase genes from 17 European Union/European Economic Area countries revealed acquisition of 18 carbapenemase variants, mainly in ST131 clades A and C. Most frequent were (n = 230) and (n = 224), detected in 14 and 12 countries, respectively. Isolates carrying have increased rapidly since 2021. The increasing detection of carbapenemase genes in the high-risk lineage ST131 is a public health concern.